Skip to main content
HairCited

スピロノラクトン 図

7 査読済み研究からの図表

すべて セレン ケラチン コラーゲン ミノキシジル デュタステリド フィナステリド スピロノラクトン ローズマリーオイル マイクロニードリング オメガ3脂肪酸 ビタミンB12 ビタミンD L-システイン MSM PRP療法 亜鉛 低出力レーザー治療 カフェイン（外用） 鉄
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Fig. 2. Ludwig scale representation
Figure 4 Diagram

The Ludwig scale classifies female pattern hair loss into three progressive stages, ranging from minimal thinning at the crown (Grade I) to extensive hair loss across the top of the scalp (Grade III). This grading system remains one of the most widely used clinical tools for assessing FPHL severity.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Fig. 3. Sinclair Scale Sinclair’s classification. MPA is divided into four levels of intensity on the basis of normal scalp to the left (Sinclair et al., 2005).
Figure 5 Diagram

Sinclair's classification divides midline pattern alopecia into four intensity levels, progressing from a normal-appearing scalp to increasingly visible widening of the central part. The scale, introduced by Sinclair et al. (2005), provides a practical visual reference for clinicians assessing hair loss severity.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Fig. 4. Olsen´s classification. Olsen patterns incorporate the accentuation of the front-overtical alopecia, which has a triangular or Christmas tree form with hair loss in a triangular form in the front-overtical area (Olsen, 2002).
Figure 6 Diagram

Olsen's classification system highlights the characteristic triangular or Christmas-tree pattern of frontovertical alopecia seen in female pattern hair loss. The accentuation of thinning at the frontal midline distinguishes this pattern from the more diffuse Ludwig classification.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Figure 2
Figure 2 Diagram

Classification systems for androgenetic alopecia severity are presented, distinguishing male and female pattern hair loss stages.

Androgenetic alopecia: An update.

Fig 3. Dihydrotestosterone (DHT) synthesis by SRD5A2 in AGA. The SRD5A2 synthesizes DHT by converting testosterone in the presence of NADPH to DHT.
Figure 3 Diagram

The DHT synthesis pathway via SRD5A2 is diagrammed, showing how 5-alpha reductase converts testosterone to dihydrotestosterone in the presence of NADPH, the key hormonal driver of AGA.

Androgenetic alopecia: An update.

Fig 4. Mechanism of inhibition by finasteride - covalent adduct between NADPH and finasteride. E57TM2 facilitates the hydride transfer to the D1,2 bond of finasteride to the covalent bond in the red circle. The covalent bond prevents a further hydride trans
Figure 4 Diagram

Finasteride's mechanism of inhibition is depicted at the molecular level, showing covalent adduct formation between NADPH and finasteride that prevents further hydride transfer to testosterone.

Androgenetic alopecia: An update.

Fig 5. The structure of human SRD5A2. (A), Spheres represent NADP-DHF adduct. L1-6 are the 6 loops connecting the 7 transmembranes (TM), and the TM portion has 254 amino acid residues. (B), The active site inside the 7 TM channels surrounded by L1, L3, an
Figure 5 Diagram

The three-dimensional structure of human SRD5A2 is shown with its seven transmembrane domains, active site, and NADP-DHF adduct positioning within the enzyme channel.

Androgenetic alopecia: An update.